Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Neurocrine Biosciences, Inc. NBIX

Set alert

Price alert · NBIX

All alert types
166.03 USD +20.68 +14.23%

As of Nov 3, 10:11 AM ET

Bid
165.88 × 1
Ask
166.48 × 1
157.91 Day range 168.24
123.10 52-week range 185.50
YTD
+17.06%
1 year
+16.96%
Open
159.00
Prev close
145.35
Mkt cap
16.84B
Vol
1.12M
Avg vol
1.25M
EPS
6.74
P/E
24.58
Div yield
0.00%
More statistics
Low
157.91
High
168.24
Forward P/E
12.14
Beta
0.33
Short ratio
4.41
Inst. own
104.46%
Dividend
0.00
Ex-div date
Dec 28, 1995
Earnings
Feb 10, 2027
50-d avg
146.63
200-d avg
147.38
1y target
206.22

MAX chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • May 5, 2026Earnings: 1.91; estimate 1.22; surprise 56.56%
  • Sep 3, 2026Rating: Citigroup · Buy → Buy
Signals (136)
NameDateAgo
SMA: BullishNov 3, 202628 minutes ago
SMA: BearishSep 1, 20262 months ago
SMA: BullishMay 1, 20266 months ago
MACD: Buy SignalMay 1, 20266 months ago
MACD: Sell SignalMar 1, 20268 months ago
SMA: BearishFeb 1, 20269 months ago
MACD: Buy SignalSep 1, 20251 year ago
SMA: BullishJun 1, 20251 year ago
SMA: BullishMay 1, 20251 year ago
SMA: BearishFeb 1, 20251 year ago
SMA: BearishFeb 1, 20251 year ago
MACD: Sell SignalFeb 1, 20251 year ago
MACD: Buy SignalJan 1, 20251 year ago
SMA: BullishDec 1, 20241 year ago
MACD: Sell SignalSep 1, 20242 years ago
SMA: BearishAug 1, 20242 years ago
MACD: Buy SignalSep 1, 20233 years ago
SMA: BullishAug 1, 20233 years ago
SMA: BullishJul 1, 20233 years ago
SMA: BearishMay 1, 20233 years ago

Newest 20 of 136.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 206.22 +24.2% upside
Target (low)
150.00
Target (mean)
206.22
Target (high)
253.00
Ratings (0m) 29 25 buy · 4 hold · 0 sell
  • Strong buy4
  • Buy21
  • Hold4
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 29
  • 1 month ago 29
  • 2 months ago 28

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

NBIX analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter2.752.07 – 3.332.17+26.5%1.04B+31.3%17
Next quarter2.812.13 – 3.651.88+49.4%1.09B+34.7%14
Current year10.248.98 – 11.406.39+60.3%3.90B+36.5%17
Next year11.978.37 – 16.0610.24+16.9%4.55B+16.6%15

Upgrades and downgrades

The latest rating changes

NBIX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 16, 2026NeedhamReiteratedBuyBuy
Oct 12, 2026BMO CapitalMaintainedMarket PerformMarket Perform
Sep 29, 2026UBSMaintainedBuyBuy
Sep 11, 2026Morgan StanleyMaintainedEqual-WeightEqual-Weight
Sep 8, 2026RBC CapitalReiteratedOutperformOutperform
Sep 3, 2026CitigroupMaintainedBuyBuy
Aug 13, 2026Morgan StanleyMaintainedEqual-WeightEqual-Weight
Aug 3, 2026Canaccord GenuityMaintainedBuyBuy
Aug 3, 2026Truist SecuritiesMaintainedBuyBuy
Aug 3, 2026WedbushMaintainedOutperformOutperform
Jul 31, 2026CitigroupMaintainedBuyBuy
Jul 31, 2026RBC CapitalMaintainedOutperformOutperform
Jul 31, 2026Morgan StanleyMaintainedEqual-WeightEqual-Weight
Jul 31, 2026TD CowenMaintainedBuyBuy
Jul 31, 2026Piper SandlerMaintainedOverweightOverweight
Jul 31, 2026Cantor FitzgeraldMaintainedOverweightOverweight
Jul 31, 2026GuggenheimMaintainedBuyBuy
Jul 31, 2026StifelMaintainedBuyBuy
Jul 31, 2026NeedhamMaintainedBuyBuy
Jul 21, 2026GuggenheimMaintainedBuyBuy
Jul 17, 2026Wells FargoMaintainedOverweightOverweight
Jul 13, 2026Truist SecuritiesMaintainedBuyBuy
Jul 13, 2026BMO CapitalMaintainedMarket PerformMarket Perform
Jul 7, 2026RBC CapitalMaintainedOutperformOutperform
Jun 30, 2026UBSMaintainedBuyBuy
May 29, 2026RBC CapitalMaintainedOutperformOutperform
May 22, 2026BernsteinInitiated—Outperform
May 8, 2026JP MorganMaintainedOverweightOverweight
May 7, 2026Truist SecuritiesMaintainedBuyBuy
May 6, 2026CitigroupMaintainedBuyBuy